10/03/2026
✨GLP1s ♾️‼️
A Post Hoc Analysis of the SURMOUNT-4 Trial:
“308 participants experienced weight reduction and improvement in cardiometabolic parameters after a 36-week tirzepatide treatment. One year after tirzepatide withdrawal, a higher degree of weight regain was associated with a greater reversal of initial improvements in waist circumference, blood pressure, non–high-density lipoprotein cholesterol, glycemic parameters, and insulin resistance.”
Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026;186(2):157–167. doi:10.1001/jamainternmed.2025.6112